Further correspondence from 'Corporate Communications' at NICE regarding the MEA request for details of people who have concluded that an update of the NICE guideline on ME/CFS is not necessary
Interesting to note that a patient representative was involved in this decision making process and that psychiatry experts outnumbered neurology experts by 3 to 2!
NB: I am now off to London so won't be around to discuss this response. But I am not gong to admit defeat at this point!
Dear Dr Shepherd
Thank you for your follow up email about the topic experts in respect of the surveillance review for the CFS/ME guideline.
In your email you refer to a request for details of membership of the expert group that reviewed the evidence for NICE. There was not a topic expert group or panel as such, but we did ask topic experts and members of the original guideline development group for their opinion.
To be clear, it is the NICE surveillance team that conducts the literature searches and reviews the evidence. They summarise the relevant evidence and highlight any studies that may have an impact on our recommendations. Information identified by the surveillance team forms the basis of the review proposal which is considered by NICE’s Guidance Executive. I can see that my colleague Alex provided details of the roles within the surveillance team in his previous response.
The final decision about whether an update is needed is based on a balanced assessment of new relevant evidence published since the guideline was developed, the view of topic experts, feedback during consultation and other sources of information on the continued relevance of the of the guideline. The findings of the check on the need for an update are discussed with topic experts. All proposals go through an internal validation process before submission to Guidance Executive. It is Guidance Executive that takes the decision to update the guidance or not.
You commented on our previous email where we say that ‘we do not
routinely publish the identities of topic experts’. The use of the word ‘routinely’ was meant to indicate that this is not part of our process, rather than they are available on request. As you may be aware we have been asked for the names of the topic experts in a freedom of information request. I can confirm that we hold the names of the topic experts who were asked for their opinion on the relevance of the published guideline. However we consider that the names are exempt from disclosure under 2 sections of the Freedom of Information Act.
For your information the topic experts are from the following fields: neurology (2), psychiatry (3), paediatrics (1), patient representative (1)
Kind regards
Janet
Janet Fahie
Communications Executive
Corporate Communications
National Institute for Health and Care Excellence
Level 1A | City Tower | Piccadilly Plaza | Manchester M1 4BT | United Kingdom
Web:
http://nice.org.uk
------------------- Original Message -------------------
From: Charles Shepherd
Received: 27/07/2017 14:58
To: NICE Mail
Subject: Re: EH82697 - CFS/ME review
Dear Alex
Thank you for your detailed reply to my request for details of membership of the expert group that has reviewed the evidence for NICE.
You say that: "
We do not routinely publish the identities of topic experts because, while they may express an opinion, they are not part of the decision making body."
The word "routinely" indicates that while publication of names of topic experts is not done as a matter of course, this is something that NICE could do if it wanted to.
And there is nothing in your reply to indicate that membership details of the group have to remain confidential.Our request to NICE is not "routine".
Earlier this week The MEA sent a letter to Sir Andrew Dillon with a petition signed by over 15,000 people calling for a review of the NICE guideline on ME/CFS.
This appears to be the largest ever public vote of no confidence in a NICE guideline by the people it is designed to help.
The fact that these experts are "not part of the decision body" has nothing to do with publishing or refusing to publish the names.
They are playing a key role in the
decision making process.So please could you clarify if NICE is actually refusing to disclose this information.
And if so on what grounds.This is a perfectly reasonable request.
The ME/CFS patient community expects transparency from NICE in the decision making process on an issue of great importance to their health and this is not happening here.
Regards
Dr Charles Shepherd
Hon Medical Adviser, MEA
MEA letter (pdf) to Sir Andrew Dillon, Chief Executive at NICE, containing the 15,000 signature petition
http://www.meassociation.org.uk/wp-...tion-Letter-to-Sir-Andrew-Dillon-24.07.17.pdf
On Wednesday, 26 July 2017, 16:08, NICE Mail <
nice@nice.org.uk> wrote:
Dear Dr Shepherd,
Thank you for contacting the National Institute for Health and Care Excellence (NICE) regarding our guideline on
chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management (CG53).
In reaching our provisional decision the surveillance review team undertook extensive searches to identify any new primary and secondary studies, including any economic studies. The focus is on the scope of the published guideline, but any additional areas or changes in practice that are identified during the process are also considered, if they fall within the referral of the published guideline. A literature search is conducted across a range of sources, selected according to their relevance to the topic and are based on those used in the published guideline.
We can’t provide the names of the surveillance team but it is made up of a Technical Analyst, Technical Adviser, Clinical Adviser and the Associate Director – Surveillance.
Topic experts, including members of the original guideline committee, are asked for their opinion, in their personal capacity, on the relevance of the published guideline, recent developments in the topic area and their knowledge of any new important evidence since publication of the guideline. Guideline committees are responsible for the development of guidelines and we publish the membership of them. We do not routinely publish the identities of topic experts because, while they may express an opinion, they are not part of the decision making body.
The review proposal is made by the review team and the decision on whether to update the guideline is made by our Guidance Executive. The Guidance Executive considers and signs off guidance and implementation for publication. It meets every week and is made up of NICE executive directors, guidance centre directors and the communications director. Its current membership can be found on the
NICE website.
I hope this information has answered your question.
Kind regards,
Alex
Alexander Smith
Communications Executive (Corporate Communications)
National Institute for Health and Care Excellence
Level 1A | City Tower | Piccadilly Plaza | Manchester M1 4BD | United Kingdom